Arrowhead, Others Keep the RNAi Faith Despite Doubters
BioWorld Insight Contributing Writer
It's been a tough few years for RNAi. Last fall, Roche AG discontinued its preclinical RNAi work, and Novartis AG declined to expand an RNAi partnership with Alnylam Pharmaceuticals Inc. Pfizer Inc. followed suit earlier this year, closing its oligonucleotide therapeutics unit.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST